Table 2. Univariate and multivariate Cox regression model in predicting progression-free and overall survival of clear cell renal cell carcinoma.
| Characteristic | Progression-free survival of FUSCC cohort | Overall survival of FUSCC cohort | ||||||
| Univariate model | Multivariate model | Univariate model | Multivariate model | |||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | 1.163 (0.874-1.548) | 0.300 | 1.334 (0.949-1.875) | 0.097 | ||||
| Laterality | ||||||||
| Left | Reference | Reference | ||||||
| Right | 1.053 (0.795-1.393) | 0.720 | 1.030 (0.735-1.443) | 0.886 | ||||
| ISUP grade | ||||||||
| I-II | Reference | Reference | Reference | Reference | ||||
| III-IV | 3.019 (2.225-4.098) | <0.001 | 2.013 (1.454-2.786) | <0.001 | 3.466 (2.364-5.083 | <0.001 | 1.954 (1.286-2.970) | 0.002 |
| Gender | ||||||||
| Male | Reference | Reference | ||||||
| Female | 0.927 (0.685-1.255) | 0.625 | 1.047 (0.732-1.498) | 0.801 | ||||
| AJCC Stage | 4.285 (3.205-5.729) | <0.001 | 2.021 (1.357-3.010) | 0.001 | 6.289 (4.440-8.907) | <0.001 | 2.515 (1.575-4.016) | <0.001 |
| pT stage | ||||||||
| T1-T2 | Reference | Reference | Reference | Reference | ||||
| T3-T4 | 4.285 (3.205-5.729) | <0.001 | 1.274 (1.087-1.492) | 0.003 | 1.297 (1.183-1.423) | <0.001 | 1.226 (1.017-1.477) | 0.032 |
| pN stage | ||||||||
| N0 | Reference | Reference | Reference | Reference | ||||
| N1 | 3.800 (2.670-5.408) | <0.001 | 1.372 (0.879-2.142) | 0.164 | 4.869 (3.314-7.154) | <0.001 | 1.396 (0.860-2.266) | 0.177 |
| M stage | ||||||||
| M0 | Reference | Reference | Reference | Reference | ||||
| M1 | 6.308 (4.354-9.138) | <0.001 | 1.919 (1.190-3.094) | 0.008 | 7.664 (5.160-11.382) | <0.001 | 1.778 (1.065-2.970) | 0.028 |
| CDH1 expression | ||||||||
| Low | Reference | Reference | Reference | Reference | ||||
| High | 0.708 (0.532-0.941) | 0.017 | 0.708 (0.513-0.977) | 0.035 | 0.466 (0.324-0.670) | <0.001 | 0.564 (0.379-0.837) | 0.005 |
| CDH2 expression | ||||||||
| Low | Reference | Reference | ||||||
| High | 0.918 (0.694-1.215) | 0.550 | 0.753 (0.536-1.060) | 0.104 | ||||
| SNAI1 expression | ||||||||
| Low | Reference | Reference | Reference | Reference | ||||
| High | 1.691 (1.277-2.240) | <0.001 | 1.360 (1.013-1.828) | 0.041 | 2.183 (1.556-3.062) | <0.001 | 1.532 (1.062-2.211) | 0.022 |
| SNAI2 expression | ||||||||
| Low | Reference | Reference | Reference | Reference | ||||
| High | 1.495 (1.125-1.988) | 0.006 | 1.207 (0.898-1.621) | 0.212 | 1.875 (1.317-2.668) | <0.001 | 1.227 (0.849-1.773) | 0.277 |
| VIM expression | ||||||||
| Low | Reference | Reference | Reference | Reference | ||||
| High | 4.406 (3.237-5.998) | <0.001 | 1.905 (1.275-2.845) | 0.002 | 4.940 (3.332-7.325) | <0.001 | 1.804 (1.042-3.122) | 0.035 |
| TWIST1 expression | ||||||||
| Low | Reference | Reference | Reference | Reference | ||||
| High | 3.121 (2.310-4.218) | <0.001 | 2.179 (1.494-3.180) | <0.001 | 2.828 (1.963-4.075) | <0.001 | 1.714 (1.088-2.700) | 0.020 |
Abbreviation: FUSCC: Fudan University Shanghai Cancer Center; ISUP: The International Society of Urological Pathology; AJCC: American Joint Committee on Cancer.